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Abstract
Flavonoids, a group of natural substances with variable phenolic structures, are found in fruits, vegetables, grains, bark, roots, stems, ﬂowers, tea and wine.
These natural products are well known for their beneﬁcial effects on health and efforts are being made to isolate the ingredients so called ﬂavonoids.
Flavonoids are now considered as an indispensable component in a variety of nutraceutical, pharmaceutical, medicinal and cosmetic applications. This
is attributed to their anti-oxidative, anti-inﬂammatory, anti-mutagenic and anti-carcinogenic properties coupled with their capacity to modulate key cellular
enzyme function. Research on ﬂavonoids received an added impulse with the discovery of the low cardiovascular mortality rate and also prevention of
CHD. Information on the working mechanisms of ﬂavonoids is still not understood properly. However, it has widely been known for centuries that deri-
vatives of plant origin possess a broad spectrum of biological activity. Current trends of research and development activities on ﬂavonoids relate to iso-
lation, identiﬁcation, characterisation and functions of ﬂavonoids and ﬁnally their applications on health beneﬁts. Molecular docking and knowledge of
bioinformatics are also being used to predict potential applications and manufacturing by industry. In the present review, attempts have been made to
discuss the current trends of research and development on ﬂavonoids, working mechanisms of ﬂavonoids, ﬂavonoid functions and applications, prediction
of ﬂavonoids as potential drugs in preventing chronic diseases and future research directions.
Key words: Flavonoids: Structure and composition: Biological activity: Research trends: Future research directions
Flavonoids are an important class of natural products; particu-
larly, they belong to a class of plant secondary metabolites hav-
ing a polyphenolic structure, widely found in fruits, vegetables
and certain beverages. They have miscellaneous favourable
biochemical and antioxidant effects associated with various
diseases such as cancer, Alzheimer’s disease (AD), atheroscler-
osis, etc.(1–3). Flavonoids are associated with a broad spectrum
of health-promoting effects and are an indispensable compo-
nent in a variety of nutraceutical, pharmaceutical, medicinal
and cosmetic applications. This is because of their antioxida-
tive, anti-inﬂammatory, anti-mutagenic and anti-carcinogenic
properties coupled with their capacity to modulate key cellular
enzyme functions. They are also known to be potent inhibitors
for several enzymes, such as xanthine oxidase (XO),
cyclo-oxygenase (COX), lipoxygenase and phosphoinositide
3-kinase(4–6).
In nature, ﬂavonoid compounds are products extracted
from plants and they are found in several parts of the plant.
Flavonoids are used by vegetables for their growth and
defence against plaques(7). They belong to a class of
low-molecular-weight phenolic compounds that are widely dis-
tributed in the plant kingdom. They constitute one of the most
characteristic classes of compounds in higher plants. Many ﬂa-
vonoids are easily recognised as ﬂower pigments in most
angiosperm families. However, their occurrence is not
restricted to ﬂowers but are found in all parts of plants(8).
Flavonoids are also abundantly found in foods and beverages
of plant origin, such as fruits, vegetables, tea, cocoa and wine;
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hence they are termed as dietary ﬂavonoids. Flavonoids have
several subgroups, which include chalcones, ﬂavones, ﬂavo-
nols and isoﬂavones. These subgroups have unique major
sources. For example, onions and tea are major dietary sources
of ﬂavonols and ﬂavones.
Flavonoids play a variety of biological activities in plants,
animals and bacteria. In plants, ﬂavonoids have long been
known to be synthesised in particular sites and are responsible
for the colour and aroma of ﬂowers, and in fruits to attract
pollinators and consequently fruit dispersion to help in seed
and spore germination, and the growth and development of
seedlings(9). Flavonoids protect plants from different biotic
and abiotic stresses and act as unique UV ﬁlters(10), function
as signal molecules, allopathic compounds, phytoalexins,
detoxifying agents and antimicrobial defensive compounds.
Flavonoids have roles against frost hardiness, drought resist-
ance and may play a functional role in plant heat acclimatisa-
tion and freezing tolerance(11). Jorgensen(12) has mentioned
that the early advances in ﬂoral genetics were primarily due
to mutation techniques making an impact on ﬂavonoid-
derived ﬂower colours, and demonstrated that functional
gene silencing in plants was associated with ﬂavonoid biosyn-
thesis. Flavonoids have been ascribed positive effects on
human and animal health and the current interest is for disease
therapy and chemoprevention. Currently there are about 6000
ﬂavonoids that contribute to the colourful pigments of fruits,
herbs, vegetables and medicinal plants. Dixon & Pasinetti(13)
reviewed plant ﬂavonoids and isoﬂavonoids in detail and dis-
cussed their applications to agriculture and neurosciences in
human beings. Kumar & Pandey(14) reviewed the protective
roles of ﬂavonoids against human diseases as well as their
functions in plants. Recently Panche et al.(15), while reviewing
AD and current therapeutic methods, discussed in detail
uses of ﬂavonoids as plant secondary metabolites for the treat-
ment of AD and the mechanisms involved. In the present
review, attempts have been made to discuss the current trends
of research and development on ﬂavonoids, their applications
as dietary and health beneﬁts along with broad classiﬁcation
and future research directions.
Classification
Flavonoids can be subdivided into different subgroups
depending on the carbon of the C ring on which the B ring
is attached and the degree of unsaturation and oxidation of
the C ring (Fig. 1). Flavonoids in which the B ring is linked
in position 3 of the C ring are called isoﬂavones. Those in
which the B ring is linked in position 4 are called neoﬂavo-
noids, while those in which the B ring is linked in position 2
can be further subdivided into several subgroups on the
basis of the structural features of the C ring. These subgroups
are: ﬂavones, ﬂavonols, ﬂavanones, ﬂavanonols, ﬂavanols or
catechins, anthocyanins and chalcones (Fig. 1).
Flavones
Flavones are one of the important subgroups of ﬂavonoids.
Flavones are widely present in leaves, ﬂowers and fruits as
glucosides. Celery, parsley, red peppers, chamomile, mint
and ginkgo biloba are among the major sources of ﬂavones.
Luteolin, apigenin and tangeritin belong to this subclass of ﬂa-
vonoids (Fig. 2). The peels of citrus fruits are rich in the poly-
methoxylated ﬂavones, tageretin, nobiletin and sinensetin(16).
They have a double bond between positions 2 and 3 and a
ketone in position 4 of the C ring. Most ﬂavones of vegetables
and fruits have a hydroxyl group in position 5 of the A ring,
while hydroxylation in other positions, for the most part in
position 7 of the A ring or 3′ and 4′ of the B ring, may
vary according to the taxonomic classiﬁcation of the particular
vegetable or fruit.
Flavonols
Flavonols are ﬂavonoids with a ketone group. They are build-
ing blocks of proanthocyanins. Flavonols occur abundantly in
a variety of fruits and vegetables. The most studied ﬂavonols
are kaempferol, quercetin, myricetin and ﬁsetin (Fig. 2).
Onions, kale, lettuce, tomatoes, apples, grapes and berries
are rich sources of ﬂavonols. Apart from fruits and vegetables,
tea and red wine are also sources of ﬂavonols. Intake of ﬂavo-
nols is found to be associated with a wide range of health ben-
eﬁts which includes antioxidant potential and reduced risk of
vascular disease.
Compared with ﬂavones, ﬂavonols have a hydroxyl group in
position 3 of the C ring, which may also be glycosylated. Like
ﬂavones, ﬂavonols are very diverse in methylation and hydrox-
ylation patterns as well and, considering the different glycosy-
lation patterns, they are perhaps the most common and largest
subgroup of ﬂavonoids in fruits and vegetables. For example,
quercetin is present in many plant foods(17).
Flavanones
Flavanones are another important class which is generally pre-
sent in all citrus fruits such as oranges, lemons and grapes.
Hesperitin, naringenin and eriodictyol are examples of this
class of ﬂavonoids (Fig. 2). Flavonones are associated with
a number of health beneﬁts because of their free radical-
scavenging properties. These compounds are responsible for
the bitter taste of the juice and peel of citrus fruits. Citrus
ﬂavonoids exert interesting pharmacological effects as antioxi-
dant, anti-inﬂammatory, blood lipid-lowering and cholesterol-
lowering agents. Flavanones, also called dihydroﬂavones, have
the C ring saturated; therefore, unlike ﬂavones, the double
bond between positions 2 and 3 is saturated and this is the
only structural difference between the two subgroups of ﬂavo-
noids. Over the past 15 years, the number of ﬂavanones has
signiﬁcantly increased(17).
Isoflavonoids
Isoﬂavonoids are a large and very distinctive subgroup of ﬂa-
vonoids. Isoﬂavonoids enjoy only a limited distribution in the
plant kingdom and are predominantly found in soyabeans and
other leguminous plants. Some isoﬂavonoids have also been
reported to be present in microbes(18). They are also found
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to play an important role as precursors for the development
of phytoalexins during plant microbe interactions(19,20).
Isoﬂavonoids exhibit tremendous potential to ﬁght a number
of diseases. Isoﬂavones such as genistein and daidzein are
commonly regarded to be phyto-oestrogens because of their
oestrogenic activity in certain animal models (Fig. 2).
Szkudelska & Nogowski reviewed the effect of genistein indu-
cing hormonal and metabolic changes, by virtue of which they
can inﬂuence various disease pathways(21).
Neoflavonoids
Neoﬂavonoids are a class of polyphenolic compounds. While
ﬂavonoids have a 2-phenylchromen-4-one backbone, neoﬂa-
vonoids have a 4-phenylchromen backbone with no hydroxyl
group substitution at position 2. The ﬁrst neoﬂavone isolated
from natural sources in 1951 was calophyllolide from
Calophyllum inophyllum seeds. It is also found in the bark and
timber of the Sri Lankan endemic plant Mesua thwaitesii(22–24).
Flavanols, flavan-3-ols or catechins
Flavanonols, also called dihydroﬂavonols or catechins, are the
3-hydroxy derivatives of ﬂavanones. They are a highly diversiﬁed
and multisubstituted subgroup. Flavanols are also referred to
ﬂavan-3-ols as the hydroxyl group is always bound to position
3 of the C ring. Unlike many ﬂavonoids, there is no double
bond between positions 2 and 3. Flavanols are found abundantly
in bananas, apples, blueberries, peaches and pears (Fig. 2).
Anthocyanins
Anthocyanins are pigments responsible for colours in plants,
ﬂowers and fruits. Cyanidin, delphinidin, malvidin, pelargoni-
din and peonidin are the most commonly studied anthocyanins
(Fig. 2). They occur predominantly in the outer cell layers of
various fruits such as cranberries, black currants, red grapes,
merlot grapes, raspberries, strawberries, blueberries, bilberries
and blackberries. Stability coupled with health beneﬁts of these
compounds facilitate them to be used in the food industry in a
variety of applications(25). The colour of the anthocyanin
depends on the pH and also by methylation or acylation at
the hydroxyl groups on the A and B rings(17).
Chalcones
Chalcones are a subclass of ﬂavonoids. They are characterised
by the absence of ‘ring C’ of the basic ﬂavonoid skeleton struc-
ture shown in Fig. 1. Hence, they can also be referred to as
open-chain ﬂavonoids. Major examples of chalcones include
Fig. 1. Basic skeleton structure of flavonoids and their classes.
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phloridzin, arbutin, phloretin and chalconaringenin. Chalcones
occur in signiﬁcant amounts in tomatoes, pears, strawberries,
bearberries and certain wheat products. Chalcones and their
derivatives have garnered considerable attention because of
numerous nutritional and biological beneﬁts. Table 1 describes
the food sources of all dietary ﬂavonoids discussed throughout
the article for their bioactivity and research trends(26–63). The
intake of ﬂavonoids through food sources could be the sim-
plest and safest way to combat diseases as well as modulate
activities.
Current research and trends on flavonoids
Anti-cholinesterase activity
Acetylcholinesterase (AChE) is a key enzyme in the central
nervous system and inhibition of it leads to increases of neural
acetylcholine levels which is one of the therapies for symptom-
atic relief of mild to moderate AD(64). Hence the inhibition of
cholinesterases is one of the central focus for drug develop-
ment to combat AD. A number of ﬂavonoids have been
reported for their anti-cholinesterase activity. The in vitro
inhibitory studies done on various ﬂavonoids like quercetin,
rutin, kaempferol 3-O-β-D-galactoside and macluraxanthone
showed that quercetin and macluraxanthone possess a
concentration-dependent inhibition ability against AChE and
butyrylcholinsterase (BChE)(34). Macluraxanthone was found
to be the most potent and speciﬁc inhibitor of both the
enzymes with 50 % inhibitory concentration (IC50) values of
8·47 and 29·8 µM, respectively. The enzyme kinetic studies
revealed that quercetin inhibited both the enzymes in a
competitive manner whereas macluraxanthone was non-
competitive against AChE and competitive against BChE.
To get insight of the intermolecular interactions, molecular
docking studies of these two compounds were performed at
active sites of both the enzymes. The docking studies showed
that macluraxanthone binds much more tightly with both the
enzymes than that of quercetin. Sheng et al.(65), while design-
ing, synthesising and performing the evaluation of ﬂavonoid
derivatives as potent AChE inhibitors, observed that most
of the ﬂavonoid derivatives have properties of inhibitory activ-
ities to AChE. The most potent inhibitor, isoﬂavone derivative
10d, inhibits AChE with an IC50 of 4 nM, showing a high
BChE:AChE inhibition ratio (4575-fold), superior to donepe-
zil (IC50 = 12 nM, 389-fold). Molecular docking studies were
also performed to explore the detailed interaction with AChE.
Anti-inflammatory activity
COX is an endogenous enzyme which catalyses the conversion
of arachidonic acid into prostaglandins and thromboxanes(66).
Fig. 2. Flavonoid classes, subclasses and natural sources.
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The enzyme exists in two isoforms, COX-1 and COX-2.
COX-1 is a constitutive enzyme and is responsible for the sup-
ply of prostaglandins which maintain the integrity of the gastric
mucosa and provide adequate vascular homeostasis whereas
COX-2 is an inducible enzyme and is expressed only after
an inﬂammatory stimulus(67). The function of COX-2 is to
synthesise prostaglandins for the induction of inﬂammation
and pain(68). The studies done by using in silico methods on
the binding modes of ﬂavonoids with COX-2 explored that
some ﬂavonols and ﬂavones containing a 2, 3-double bond
may act as preferential inhibitors of COX-2(69). These observa-
tions were found for the ﬂavonol, ﬂavone, and ﬂavanone or
isoﬂavone classes. This discovery led to the development of
selective COX-2 inhibitors which are a class of compounds
with good anti-inﬂammatory activity and reduced gastrointes-
tinal side effects. The commercially available ﬂavonoids like
silbinin, galangin, scopoletin, hesperitin, genistein, daidzein,
esculatin, taxifolin, naringenin and celecoxib were also evalu-
ated for COX-inhibitory activity(70). The selected ﬂavonoids
showed higher binding energy ranging between −8·77
to −6·24 kcal/mol (–36·69 to –26·11 kJ/mol) when com-
pared with that of the standard (−8·30 kcal/mol; –34·73
kJ/mol) which led to the development of potent COX inhibi-
tors for the treatment of inﬂammation. Madeswaran et al.(70)
evaluated the COX-inhibitory activity of ﬂavonoids using in
silico docking studies. In this perspective, they used ﬂavonoids
like farobin-A, gericudranin-B, glaziovianin-A, rutin and
xanthotoxin. Their docking results showed that all the selected
ﬂavonoids contributed better aldose reductase inhibitory activ-
ity because of their structural parameters. Hence, further dee-
per studies could develop potent aldose reductase inhibitors
for the treatment of diabetes. Madeswaran et al.(71) also
reported in silico docking studies of lipoxygenase-inhibitory
activity of commercially available ﬂavonoids. In this perspec-
tive, they selected ﬂavonoids like aromadedrin, eriodictyol,
ﬁsetin, homoeriodictyol, pachypodol, rhamnetin, robinetin,
tangeritin, theaﬂavin and azelastine for investigation. It was
observed that all the selected ﬂavonoids contributed to
lipoxygenase-inhibitory activity because of their structural
parameters and the whole analysis could lead to the further
Table 1. Flavonoids, their classes and rich dietary sources
Serial
no. Flavonoid Class Dietary sources References
1 Quercetin Flavonols Vegetables, fruits and beverages, spices, soups, fruit
juices
Hertog et al.(26); Justesen &
Knuthsen(27); Stewart et al.(28); Zheng &
Wang(29)
2 Rutin Flavonols Green tea, grape seeds, red pepper, apple, citrus
fruits, berries, peaches
Atanassova & Bagdassarian(30);
Gudrais(31); Chang et al.(32); Malagutti
et al.(33)
3 Macluraxanthone Xanthones Maclura tinctoria (Hedge apple), Dyer’s mulberry Khan et al.(34)
4 Genistein Isoflavone Fats, oils, beef, red clover, soyabeans, psoralea,
lupin, fava beans, kudzu, psoralea
Thompson et al.(35); Umpress et al.(36);
Krenn et al.(37); Coward et al.(38);
Kaufman et al.(39)
5 Scopoletin Coumarin Vinegar, dandelion coffee Gálvez et al.(40)
6 Daidzein Isoflavone Soyabeans, tofu Zhang et al.(41)
7 Taxifolin Flavanonol Vinegar Cerezoa et al.(42)
8 Naringenin Flavanone Grapes Felgines et al.(43)
9 Abyssinones Flavanone French bean seeds Rathmell & Bendall(44); Cruickshank
et al.(45)
10 Rutin Flavonol Citrus fruits, apple, berries, peaches Cruickshank et al.(45); Chang et al.(32)
11 Eriodictyol Flavanone Lemons, rosehips Hvattum(46)
12 Fisetin Flavonol Strawberries, apples, persimmons, onions,
cucumbers
Sahu et al.(47)
13 Theaflavin Catechins Tea leaves, black tea, oolong tea Leung et al.(48)
14 Peonidin Anthocyanidin Cranberries, blueberries, plums, grapes, cherries,
sweet potatoes
Truong et al.(49)
15 Diosmetin Flavone Vetch Andreeva et al.(50)
16 Tricin Flavone Rice bran Cai et al.(51)
17 Biochanin Isoflavone Red clover, soya, alfalfa sprouts, peanuts, chickpeas
(Cicer arietinum), other legumes
Medjakovic & Jungbauer(52)
18 Hesperidin Flavanone Bitter orange, petit grain, orange, orange juice, lemon,
lime
National Agricultural Library(53); Khan
et al.(34)
19 Epicatechin Flavan-3-ols Milk, chocolate, commercial, reduced fat Arts et al.(54)
20 Myricetin Flavonols Vegetables, fruits, nuts, berries, tea, red wine Ross & Kasum(55); Basli et al.(56)
21 Taxifolin Flavanonol Citrus fruits Grayer & Veitch(57); Kawaii et al.(58)
22 Kaempferol Flavonols Apples, grapes, tomatoes, green tea, potatoes,
onions, broccoli, Brussels sprouts, squash,
cucumbers, lettuce, green beans, peaches,
blackberries, raspberries, spinach
Calderon-Montaño et al.(59); Liu(60); Kim
& Choi(61)
23 Luteolin Flavones Celery, broccoli, green pepper, parsley, thyme,
dandelion, perilla, chamomile tea, carrots, olive oil,
peppermint, rosemary, navel oranges, oregano
Kayoko et al.(62); López-Lázaro(63)
24 Apigenin Flavones Milk, chocolate, commercial, reduced fat Hertog et al.(26)
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development of potent drugs for the treatment of inﬂamma-
tion. Wu et al.(72) worked on antiplatelet effects and selective
binding of COX with ﬂavonoids and lignans by using the
molecular docking method. The ﬂavonoids considered were
ginkgetin, Taiwan-homo-ﬂavone A, Taiwan-homo-ﬂavone B
and Taiwan-homo-ﬂavone C and eight known lignans justici-
din B, justicidin C, justicidin D, chinensinaphthol methyl
ether, procumphthalide A, procumbenoside A and ciliatosides
A and B from medicinal herbal plants, Cephalotaxus wilsoniana
and Justicia species, respectively. Out of these ﬂavonoids gink-
getin, Taiwan-homo-ﬂavone C, justicidin B and justicidin D
were found to be effective for antiplatelet effects.
Steroid-genesis modulators
Abyssinones and related ﬂavonoids can be used as potential
steroid-genesis modulators against three enzymes 3β-
hydroxysteroid dehydrogenase (HSD), 17β-HSD and aroma-
tase of the steroid-genesis pathway(73). The virtual screening
experiment indicated higher afﬁnity for ﬂavonones than their
respective chalcones. The ﬂavonones possess consistent bind-
ing afﬁnity to all the three enzymes used and are better steroi-
dogenesis modulators in hormone-dependent cancer.
Xanthine oxidase modulators
XO catalyses the conversion of hypoxanthine to xanthine and
subsequently xanthine to uric acid. The increase of uric acid
level in blood serum, which is called hyperuricaemia, can
lead to major complications such as gout and kidney
stones(74,75). Alnajjar(76) worked on natural ﬂavonoids towards
the discovery of a potential XO inhibitor. Licoisoﬂavone-A
extracted from the roots of Glycyrrhiza glabra (liquorice)
showed the most potent activity in the inhibition of XO.
Umamaheswari et al.(77) evaluated XO-inhibitory activity of ﬂa-
vonoids using in silico docking studies. The ﬂavonoids butein,
ﬁsetin, diosmetin, tricetin, genistein, tricin, vitexycarpin, herba-
cetin, biochanin, rhamnetin, isorhamnetin, robinetin, peonidin
and okanin were studied and it was found that all ﬂavonoids
exerted inhibition activity. The presence of a benzopyran
ring in their basic nucleus would have contributed to its
XO-inhibitory activity. This molecular docking analysis may
further lead to the development of potent XO inhibitors for
the prevention and treatment of gout and related inﬂammatory
ailments. New drugs for the inhibition of the enzyme aldose
reductase are in development and efforts are being made for
their preclinical and clinical evaluation.
A novel approach emphasising the signiﬁcance of natural
products as a prime solution to unanswered questions like
the treatment of the ‘silent killer’ ‘polycystic kidney disease’
(PKD) has been investigated(78). The key protein, namely cys-
tic ﬁbrosis transmembrane conductance regulator (which is
responsible for PKD), and its mutated three-dimensional
structure were subjected to molecular docking and in silico tox-
icity studies with ﬂavonoids from vegetable sources. The out-
come indicated the possible application of ﬂavonoids from
vegetable sources as potential and natural therapeutic agents
to combat PKD.
Lin et al.(79) carried out in vitro kinetic studies of different ﬂa-
vonoids as inhibitors with various xanthine concentrations. In
vitro studies and kinetic measurements of different ﬂavonoids
and various concentrations of xanthine were carried out(79).
Four potent XO inhibitors were found in 95 % ethanolic
(v/v) gnaphalium afﬁne extract. Among them, the ﬂavone eupa-
tilin exhibited the strongest inhibitory effect on XO compared
with allopurinol, a known synthetic XO inhibitor. Apigenin,
luteolin and 5-hydroxy-6, 7, 3′, 4′-tetramethoxyﬂavone also con-
tributed to the inhibitory effect of gnaphalium afﬁne extract on
XO activity. This study provides a rational basis for the trad-
itional use of gnaphalium afﬁne against gout. The study on in
vitro XO-inhibitory activity of the aglycone hesperetin and
its glycosylated forms (hesperidin and G-hesperidin)
and their effects on the plasma lipid proﬁle and the oxida-
tive–antioxidative system has been carried out in rats(80). The
concentrations of the major conjugated metabolites in rat
plasma after oral administration of these compounds were
also determined. It has been reported that hesperetin was
found to have a stronger XO-inhibitor activity than the glyco-
sylate derivatives.
Countering antibiotic resistance
β-Ketoacyl acyl carrier protein synthase III (KAS III), which
initiates fatty acid synthesis in bacteria, is a key target enzyme
to overcome the antibiotic resistance problem. Lee et al.(81),
while working on the known ﬂavonoid inhibitors of β-KAS
III against the methicillin-resistant bacteria Staphylococcus aureus,
found that ﬂavonoids such as naringenin (5,7,4′-trihydroxyﬂa-
vanone) and eriodictyol (5,7,3′,4′-tetrahydroxyﬂavanone) are
potent antimicrobial inhibitors of Staphylococcus aureus KAS
III. Ganugapati et al.(82) worked on in silico modelling and
docking studies of a superbug enzyme, namely New Delhi
metallo-β-lactamase-1 (NDM-1), which is an enzyme found
in Escherichia coli. It has been reported that this enzyme belongs
to a B1 subclass of metallo β-lactamases and is known to
induce resistance to standard intravenous antibiotics. Similar
studies were carried out on inhibition of NDM-1 in superbugs
by ﬂavonoids using the technique of in silico molecular dock-
ing(83). At present, there are no effective antibiotics against
the NDM-1-positive pathogen and therefore this study pro-
vides clues to investigate the molecular basis of extended anti-
biotic resistance of NDM-1 and then accelerate the search for
new antibiotics against the NDM-1-positive strain in clinical
studies. Quercetin and its analogue penta-O-ethylquercetin
were found to be potential inhibitors of NDM-1.
Disease-combating activity
Ganugapati et al.(84) studied green tea ﬂavonoids as insulin
mimetics. Diabetes mellitus is a metabolism disorder where
glucose, a principal source of energy, cannot enter the cells
due to deﬁciency of insulin. The study suggested that epicate-
chin acts as an insulin receptor activator and reduces the harm-
ful effects of diabetes. Lu & Chong(85) carried out the
computational work to predict the binding modes of ﬂavonoid
derivatives with the neuraminidase of the 2009 haemagglutinin
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1 neuraminidase (H1N1) inﬂuenza virus. They employed
molecular dynamics simulation techniques to optimise the
2009 H1N1 inﬂuenza neuraminidase X-ray crystal structure.
All the twenty ﬂavonoid derivatives were found to be satisfac-
tory in binding and inhibiting the activity of the virus. These
ﬁndings may help to develop a potential drug form of the ﬂa-
vonoid derivatives for the treatment of H1N1 inﬂuenza dis-
ease. Cardenas et al.(86) showed through a study on mice that
apigenin, a dietary ﬂavonoid, exerts immune-regulatory
activity. The study carried out on NF-κB luciferase transgenic
mice showed effective modulation of NF-κB with no effect on
the rate of cell death, a decrease in lipopolysaccharide-induced
apoptosis in lungs, and inﬁltration of inﬂammation, leading to
re-establishment of normal lung architecture. These effects
indicate the immune-regulatory roles of ﬂavonoids. Kim
et al.(87) reported that a ﬂavonoid-rich diet is associated with
a reduced risk of CVD. The study focused on individual as
well as total ﬂavonoid diet effects. Higher ﬂavonoid intake
was found to be associated with the improved CVD risk fac-
tors. Mulvihill et al.(88) focused on the ability of citrus ﬂavo-
noids to modulate lipid metabolism and other metabolic
parameters related to the metabolic syndrome. This is one
of the recent trends which have focused on citrus ﬂavonoids
as potential therapeutic agents for the treatment of metabolic
dysregulation. The observational studies done by Hügel
et al.(89) indicated that dietary ﬂavonoids are associated with
a decreased risk of hypertension and CVD. A diet rich in all
ﬂavonoid classes through herbs and beverages improves vas-
cular health leading to a reduced risk of diseases. It has
been observed that the consumption of them is associated
with improvement in endothelial function via vascular endo-
thelial nitric oxide synthase and protein kinase B (Akt) activa-
tion. The effect of regular quercitin intake on blood pressure in
overweight and obese patients with pre-hypertension and stage
I hypertension was studied in seventy patients. Ambulatory
blood pressure and ofﬁce blood pressure were measured. It
was observed that the blood pressure level was reduced in
patients with hypertension(90).
Recently it has been reported that an apple of the type
pelingo is rich in food components that can markedly inhibit
in vitro tumorigenesis and the growth of human breast cancer
cells(91). It was observed that pelingo juice induced cell accu-
mulation in the G2/M phase of the cell cycle, autophagy,
inhibition of extracellular signal-regulated kinases 1/2
(ERK1/2) activity and an increase in lipidated microtubule-
associated protein-1 light chain-3β (LC3B). Hence it could
be used as a source of bioactive compounds with potential
chemopreventive activity. Through the review of randomised
controlled trials, it has been observed that intake of puriﬁed
and extract forms of anthocyanins leads to signiﬁcant
improvement in LDL-cholesterol with no adverse effects(92).
An in vivo study model of rats was used to examine the effect
of fenugreek seeds on renal pathology in alcoholics(93). The
different concentrations of seeds and their exerted effects
were checked through transmission electron microscopy.
The results showed reduction in cell deterioration and
improvement in renal morphology and function. A tannin-rich
extract obtained from the pinhão (Araucaria angustifolia) seed
was found to inhibit α-amylase(94). The same extract was
also examined for inhibition of pancreatic lipase. An effective
level of inhibition was observed for pancreatic lipase also. The
extract also showed a signiﬁcant reduction in TAG levels in
mice. These results indicate that tannin can be used as a poten-
tial molecule for anti-obesity(95). An extract of mixed poly-
phenolic compounds of grape seeds was found to comprise
the ability to inhibit the aggregation and oligomerisation of
β-amyloid in vitro and also improve the behavioural deﬁcits
in a mouse model of AD(96). Paris et al.(97) worked on ﬂavo-
noids which lower Alzheimer’s amyloid protein (Aβ) produc-
tion via a nuclear factor κ-light-chain-enhancer of activated
B cells (NF-κB)-dependent mechanism. It is well known
that AD is due to the accumulation of Aβ peptides and the
presence of neuroﬁbrillary tangles in the brain(98,99). Aβ is
believed to play an important role in AD and it has been
shown that certain ﬂavonoids such as genistein, quercetin, taxi-
folin, kaemferol, luteolin, apigenin, daidzein, aminogeneistein,
and α- and β-napthofalvone can affect Aβ production.
Recently, it was suggested that the Aβ-lowering properties of
ﬂavonoids are mediated by a direct inhibition of β active site
cleavage enzyme-1 (BACE-1) activity, the rate-limiting enzyme
responsible for the production of Aβ peptides(97). It has been
reported that a strong correlation exists between the inhibition
of NF-κB activation by ﬂavonoids and their Aβ-lowering
properties, suggesting that ﬂavonoids inhibit Aβ production
in whole cells via NF-κB-related mechanisms. As NF-κB
has been shown to regulate BACE-1 expression, it has been
concluded that NF-κB-lowering ﬂavonoids inhibit BACE-1
transcription in human neuronal cells. Shimmyo et al.(100),
while working on structure–activity relationships in cell-free,
cell-based and in silico modes revealed novel pharmacophore
features of ﬂavonoids. Their results contributed to the devel-
opment of new BACE-1 inhibitors by certain natural ﬂavo-
noids (myricetin, quercetin, kaempherol, morin, apigenin) for
the treatment of AD. Swaminathan et al.(101) worked on a ser-
ies of natural and synthetic ﬂavones and ﬂavonols to explore
their activity against radio ligand binding at human cloned
muscarinic receptors. It has been mentioned that muscarinic
acetylcholine receptor-active compounds have potential to
treat AD(102). Their ﬁndings indicated that there are several ﬂa-
vonoid compounds which possess competitive binding afﬁn-
ity, comparable with that of acetylcholine. Molecular
modelling studies suggested that the compounds bind to the
orthosteric site of the receptor, mainly through non-polar
interactions. Further, it is mentioned that due to limitations
in the docking and scoring functions used, no signiﬁcant
energy differences were observed for binding of the active
compounds compared with the inactive compounds. These
results give an indication of the potential of ﬂavonoid com-
pounds for the treatment of AD.
Flavonoid mechanisms
Almost every group of ﬂavonoids has a capacity to act as anti-
oxidants. It has been reported that the ﬂavones and catechins
seem to be the most powerful ﬂavonoids for protecting the
body against reactive oxygen species. Body cells and tissues
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are continuously threatened by the damage caused by free radi-
cals and reactive oxygen species, which are produced during
normal oxygen metabolism or are induced by exogenous dam-
age(103,104). The mechanisms and the sequence of events by
which free radicals interfere with cellular functions are not
fully understood, but one of the most important events
seems to be lipid peroxidation, which results in cellular mem-
brane damage. This cellular damage causes a shift in the net
charge of the cell, changing the osmotic pressure, leading to
swelling and eventually cell death. Free radicals can attract vari-
ous inﬂammatory mediators, contributing to a general inﬂam-
matory response and tissue damage. To protect themselves
from reactive oxygen species, living organisms have developed
several effective mechanisms(105). The antioxidant defence
mechanisms of the body include not only the enzymes such
as superoxide dismutase, catalase and glutathione peroxidase,
but also non-enzymic counterparts such as glutathione, ascor-
bic acid and α-tocopherol. The increased production of react-
ive oxygen species during injury results in consumption and
depletion of the endogenous scavenging compounds.
Flavonoids may have an additive effect to the endogenous
scavenging compounds(106). Codorniu-Hernández et al.(107)
carried out docking studies to understand ﬂavonoid–protein
interactions. The results indicated that hydrophilic amino
acid residues demonstrate high-afﬁnity interactions with ﬂa-
vonoid molecules, as was predicted by the theoretical afﬁnity
order. The docking modes among catechin molecules and
four proteins (human serum albumin, transthyretin, elastase
and renin) are also supporting this information. The theoretical
afﬁnity order among ﬂavonoids and amino acid residues seems
to have great applications in the theoretical predictions of ﬂa-
vonoid–protein interactions as a high-quality approach to
understand the biological activity of ﬂavonoids.
Radical scavenging
Flavonoids can prevent injury caused by free radicals in vari-
ous ways and one way is the direct scavenging of free radicals.
Flavonoids are oxidised by radicals, resulting in a more stable,
less-reactive radical. In other words, ﬂavonoids stabilise the
reactive oxygen species by reacting with the reactive com-
pound of the radical. Because of the high reactivity of the
hydroxyl group of the ﬂavonoids, radicals are made inactive,
as explained in the following equation as given by Korkina
& Afanasev(108):
Flavonoid (OH) + r(O) + RH,
where R is a free radical and O is an oxygen free radical.
Hanasaki et al.(109) found that some of the ﬂavonoids can dir-
ectly scavenge superoxides, whereas other ﬂavonoids can scav-
enge the highly reactive oxygen-derived radical called
peroxynitrite. They found that ﬂavonoids such as epicatechin
and rutin are powerful radical scavengers and the scavenging
ability of rutin may be due to its inhibitory activity on the
enzyme XO. Kerry & Abbey(110) reported that by scavenging
radicals, ﬂavonoids can inhibit LDL oxidation in in vitro stud-
ies. They further mentioned that this action protects the LDL
particles and, theoretically, ﬂavonoids may have preventive
action against atherosclerosis.
Xanthine oxidase inhibition
Sanhueza et al.(111) worked on changes in the xanthine
dehydrogenase:XO ratio in the rat kidney subjected to ischae-
mia–reperfusion stress and also studied the preventive effect
of some ﬂavonoids. They mentioned that the XO pathway
is an important route in the oxidative injury to tissues, espe-
cially after ischaemia–reperfusion. Xanthine dehydrogenase is
the form of the enzyme present under physiological condi-
tions, but its conﬁguration is changed to XO during ischaemic
conditions. XO is a source of oxygen free radicals. In the
reperfusion phase (reoxygenation), XO reacts with molecular
oxygen, thereby releasing superoxide free radicals. Two ﬂavo-
noids, quercetin and silibin, were found to inhibit XO activity,
thereby resulting in decreased oxidative injury(112,113). Cos
et al.(114) worked on structure–function relations in which the
ﬂavonoid luteolin (tetrahydroxyﬂavone) was reported to be
the most potent inhibitor of XO.
Anti-inflammation
Nijveldt et al.(106) reported about how immobilisation of leuco-
cytes in the blood vascular system can damage tissues through
the release of oxidants and inﬂammators. They mentioned in
their paper that the immobilisation and ﬁrm adhesion of leu-
cocytes to the endothelial wall lead to the formation of oxygen-
derived free radicals and also release of cytotoxic oxidants and
inﬂammatory mediators. Under normal conditions, leucocytes
move freely along the endothelial wall. However, during
ischaemia and inﬂammation, various endothelium-derived
mediators and complement factors may cause adhesion of
the leucocytes to the endothelial wall, thereby immobilising
them and stimulating degranulation of the neutrophil. As a
result, oxidants and inﬂammatory mediators are released,
resulting in injury to tissues. Friesenecker et al.(115), while work-
ing on the oral administration of a puriﬁed micronised ﬂavon-
oid fraction, found that the ﬂavonoids suppresses leucocyte
adhesion in ischaemia–reperfusion injury in hamsters. The
decrease in the number of immobilised leucocytes by
ﬂavonoids may be related to the decrease in total serum com-
plement and is a protective mechanism against inﬂammation-
like conditions associated with reperfusion injury(116). Some
ﬂavonoids have been shown to inhibit degranulation of neu-
trophils without affecting superoxide production(117).
Compared with the research work done on the antioxidant
capacities of ﬂavonoids, there has been relatively little research
on other possible mechanisms. One such mechanism by
which ﬂavonoids act is through interaction with various
enzyme systems. Furthermore, some effects may be a result
of a combination of radical scavenging and an interaction
with enzyme functions(107). Alcaraz & Ferrandiz(118), while
working on anti-inﬂammatory activity and the inhibition of
arachidonic acid metabolism by ﬂavonoids, reported that ﬂa-
vonoid inhibit the metabolism of arachidonic acid through
the enzyme pathway. This feature gives ﬂavonoids anti-
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inﬂammatory and anti-thrombogenic properties. The release
of arachidonic acid is a starting point for a general inﬂamma-
tory response and neutrophils containing lipoxygenase create
chemotactic compounds from arachidonic acid.
Combating neurodegenerative diseases
The recent studies on different plant metabolites have shown
that ﬂavonoids may perform a key role in enzyme and receptor
systems of the brain, exerting signiﬁcant effects on the central
nervous system, like prevention of the neurodegeneration asso-
ciated with AD and Parkinson’s disease(15,119). Flavonoids are
capable of inhibiting enzymes, as there exist strong reports
about inhibitory enzymes such as aldose reductase, XO,
phosphodiesterase, Ca2+ ATPase, lipoxygenase and COX in
preventive neurodegenerative diseases.
Considerable work has been carried out to search suitable
and new ﬂavonoids for therapeutic use in AD by using the
technique of molecular docking. Hu et al.(120) have designed
a new series of ﬂavonoids, evaluated them and discovered
potent AChE inhibitors. Most of them showed more potent
inhibitory activities against AChE than rivastigmine, an AD
drug. Further, it was mentioned that the isoﬂavone skeleton
would be a promising structural template for the development
of novel AChE inhibitors. Khan(34) has examined AChE- and
BChE-inhibitory activities of four ﬂavonoid derivatives –
quercetin, rutin, kaempferol galactoside and macluraxanthone.
Out of four ﬂavonoids, macluraxanthone displayed a
concentration-dependent inhibition of AChE and BChE. A
number of ﬂavonoids were studied to lower Alzheimer’s Aβ
production using molecular docking studies. It has been
reported that there exists a strong correlation between ﬂavo-
noids and inhibitions of NF-κB-related mechanisms. While
doing work on the molecular docking of ﬂavones as
BACE-1 inhibitors, it has been found that the ﬂavonoids
potently inhibit BACE-1 activity through the interactions of
ﬂavonoids with the BACE-1 catalytic centre(100).
Functions and applications of flavonoids
Plants produce a vast and diverse assortment of organic com-
pounds, the great majority of which do not appear to partici-
pate directly in growth and development. These substances,
traditionally referred to as secondary metabolites (ﬂavonoids),
often are differentially distributed among limited taxonomic
groups within the plant kingdom(121). The ﬂavonoids are cate-
gorised in different classes as alkaloids, terpenoids and pheno-
lics. Flavonoids carry out a number of protective functions in
the human body (Fig. 3). Many ﬂavonoids have evolved as
bioactive compounds that interfere with nucleic acid or
proteins and show antimicrobial or insecticidal and pharmaco-
logical properties. Flavonoids are therefore of interest in
medicine as therapeutics and at the same instance in agricul-
ture as pesticides(122). In vitro technology has given new insight
to explore the potency of plant cell tissue culture to produce
the same valuable chemical compounds as those of the
parent plant(123). The advancement in plant tissue culture
methods for ﬂavonoid production has bloomed beyond
expectations(124). Plant tissue culture is an aseptic technique
whereby proper manipulation of the nutrients, culture condi-
tions, and phyto-hormone supply, one may be able to produce
the desired quality and quantity of plants as well as metabo-
lites. With the culture of differentiated cells it is possible to
obtain production of the desired compounds in levels compar-
able with that of the plant. Flavonoids are associated with a
broad spectrum of health-promoting effects. They are an indis-
pensable component in a variety of nutraceutical, pharmaceut-
ical, medicinal and cosmetic applications. This is attributed to
their antioxidative(125), anti-inﬂammatory(126), anti-mutagenic(127)
and anti-carcinogenic(128) properties coupled with their capacity
to modulate key cellular enzyme functions(129). Flavonoids act
in plants as antioxidants, antimicrobials, photoreceptors, visual
attractors, feeding repellents, and for light screening. Many stud-
ies have suggested that ﬂavonoids exhibit biological activities,
including anti-allergenic, antiviral, anti-inﬂammatory and vasodi-
lating actions. However, most interest has been devoted to the
antioxidant activity of ﬂavonoids which is due to their ability
to reduce free radical formation and to scavenge free radicals.
The capacity of ﬂavonoids to act as antioxidants in vitro has
been the subject of several studies in the past years, and import-
ant structure–activity relationships of the antioxidant activity
have been established(125,130). Ren et al.(130), in their paper on ﬂa-
vonoids and anticancer agents, gave the major molecular
mechanisms of actions in different situations. In preventing car-
cinogens they mentioned that ﬂavonoids exert their effects on
cytochrome P450 to inhibit the activities of certain P450 iso-
zymes which are responsible for the production of a number
of procarcinogens. Another mechanism of action they reported
is that ﬂavonoids help in the production of metabolising
enzymes such as gluthione-S-transferase, quinone reductase
and uridine 5-diphospho-glucuronyl transferase by which carci-
nogens are detoxiﬁed and thus eliminated from the body. This
would also help in preventing the chemotherapy effect of ﬂavo-
noids against carcinogens.
A number of studies have been carried out on properties of
antioxidant in relation to different ﬂavonoids and these studies
emphasised that the ﬂavonoids can be used as potential drugs
to prevent oxidative stresses(131–136). Antioxidants are com-
pounds that protect the cells against the oxidative effect of
reactive oxygen species, and the impaired balance between
these reactive oxygen species and antioxidants results in oxida-
tive stress. The oxidative stress may lead to cellular damage
which is related to various health ailments such as diabetes,
cancer, CVD, neurodegenerative disorders and ageing.
Oxidative stress can also damage many biological molecules
and proteins and DNA molecules are signiﬁcant targets of cel-
lular injury. Antioxidants interfere with radical-producing sys-
tems and increase the function of endogenous antioxidants,
protecting the cells from damage by these free radicals(125).
Pietta(137) reviewed the current knowledge on structural
aspects and in vitro antioxidant capacity of most common ﬂa-
vonoids as well as in vitro antioxidant activity and effects on
endogenous antioxidants. Flavonoids have been found to be
very effective in preventing lipid peroxidation and lipid perox-
idation is responsible for various diseases such as atheroscler-
osis, diabetes, hepatotoxicity and inﬂammation, along with
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ageing(138–140). Studies have indicated that quercetin helps to
suppress lipid peroxidation(141). In addition to quercetin,
there are other ﬂavonoids such as myricetin, quercetrin and
rutin which help to inhibit the production of superoxide
radicals(103,104).
Flavonoids have also been recognised for their antimicrobial
activity and many researchers have isolated and identiﬁed the
structures of ﬂavonoids having properties of antifungal, anti-
viral and antibacterial activity. Because of this property,
many ﬂavonoids are now being used extensively in the ﬁelds
of nutrition, food safety and health. The antiviral effect of ﬂa-
vonoids has been shown by Wang et al.(142), particularly in
therapy for viral infection. Flavonoids such as quercetin, nar-
ingin, hesperetin and catechin possess a variable degree of anti-
viral activity. They affect the replication and infectivity of
certain RNA and DNA viruses(143). Quercetin and apigenin
are among the most studied ﬂavonoids which have been
known to exhibit antibacterial activities(144). Li & Xu(145)
have reported that quercetin extracted from lotus leaves may
be a promising antibacterial agent for periodontitis.
Some ﬂavonoids show hormone-like activities and they bear
a resemblance to steroid hormones, particularly with oestro-
gen. Such ﬂavonoids are present in fruits and vegetables, tea,
red wine and cereals(125). Hormone-like steroids are well
known in protection against various chronic diseases, espe-
cially oestrogen, which has neuroprotective effects on the
brain. A number of ﬂavonoids such as genistein, daidzein
and equol have been studied to assess their oestrogenic activity
in clinical trials. The studies determined their potential for
treatment of various chronic diseases such as cancer, cardio-
vascular disorders and osteoporosis(146,147). From their studies
it is found that the ﬂavonoid genistein has the most promising
effect in preventing postmenopausal bone loss in women. A
number of ﬂavonoids of dietary signiﬁcance have been
shown to impart beneﬁcial impact on parameters associated
with atherosclerosis, including lipoprotein oxidation, blood
platelet aggregation and cardiovascular reactivity(148,149).
Comalada et al.(150) reviewed the effects of ﬂavonoids, particu-
larly quercetin, on a variety of inﬂammatory processes and
immune functions and it has been shown that certain ﬂavo-
noids help in inhibiting the initial process of inﬂammation
and improve the immune system. Anti-inﬂammatory activity
using ﬂavonoids and tannins from the leaves of the plant Spi-
lanthes paniculata has been recently reported(126). Anticancer
effects of ﬂavonoids such as tangeritin, 3-hydroxyﬂavone,
3′,4′-dihydroxyﬂavone, 2′,3′-dihydroxyﬂavone, ﬁsetin, api-
genin, luteolin daidzein and genistein have been carried out
by a number of researchers(151–154). Ren et al.(130) and Huang
et al.(155), while working on natural phenolic compounds and
their potential use for cancer prevention, reported that various
ﬂavonoids such as tannins, stilbenes, curcuminoids, coumar-
ins, lignans, quinones and other ﬂavonoids have chemopre-
ventive properties and also contribute to induce apoptosis
by arresting the cell cycle, regulating carcinogen metabolism
and ontogenesis expression. While explaining the possible
mechanism of ﬂavonoids in cancer prevention they further
mentioned that the ﬂavonoids have complementary and over-
lapping mechanisms of action including antioxidant activity
and scavenging free radicals, modulation of carcinogen metab-
olism, regulation of gene expression on oncogenes and
tumour-suppressor genes in cell proliferation and differenti-
ation, induction of cell cycle arrest and apoptosis, modulation
of enzyme activities in detoxiﬁcation, oxidation and reduction,
anti-inﬂammatory properties and action on other possible tar-
gets. Flavonoids and their effect of protection of the central
nervous system are concerned particularly with those related
Fig. 3. Cumulative representation of roles of flavonoids in various bioactivities, human health and agriculture. BChE, butyrylcholinesterase; AChE, acetylcholines-
terase; BACE-1, β active site cleavage enzyme-1; NDM-1, New Delhi metallo-β-lactamase-1; H1N1, haemagglutinin 1 neuraminidase 1.
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to neurodegenerative disease caused by the combined effect of
oxidative stress, inﬂammation and transition metal accumula-
tion; a good amount of information is available. Alzheimer’s
and related dementias are among some of the major disorders
of neurodegeneration. Flavonoids, like ﬂavonols, are asso-
ciated with lower population rates of dementia(156). Similarly,
Hwang & Yen(157) and Jager & Saaby(119) suggested that citrus
ﬂavanones such as hesperidin, hesperetin and naringenin could
traverse the blood–brain barrier and may play an effective role
in the intervention for neurodegenerative diseases. The role of
ﬂavonoids in antidiabetic activity and anti-ageing has also been
reported(158–161).
Future research and development programmes
Flavonoids have received much attention in the literature over
the past 10 years and a variety of potential beneﬁcial effects
have been elucidated. However, a number of studies carried
out involved in vitro and in silico studies. Therefore, further
studies are needed so that the usefulness of ﬂavonoids in
the diet could be improved for better human health. The
study of ﬂavonoids is complex because of the heterogeneity
of the different molecular structures and the scarcity of data
on bioavailability. Furthermore, insufﬁcient methods are avail-
able to measure oxidative damage in vivo and the measurement
of objective end points remains difﬁcult. There is a need to
improve analytic techniques to allow the collection of more
data on absorption and excretion. Data on the long-term con-
sequences of chronic ﬂavonoid ingestion are especially scarce.
A number of reports have emphasised that molecular docking
studies are required to identify the potential molecules of ﬂa-
vonoids for their usage in the treatment of various ailments in
the human health system. The interactions of ﬂavonoids with
receptor molecules during the treatment of acute and chronic
diseases are an important area of future research. More and
more research is needed to discover new ﬂavonoids from nat-
ure’s bounty so that this will replace the use of synthetic med-
icines which are harmful to the body. In this context there is a
need of research and development programmes involving in
vivo studies which will give a hopeful and safe picture for the
future. Currently, the intake of fruit, vegetables and beverages
containing ﬂavonoids is recommended, although it is too early
to make recommendations on daily ﬂavonoid intakes.
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